Cadonilimab rechallenge in patients with recurrent or metastatic cervical cancer following prior PD-1/PD-L1 inhibitor failure: a retrospective multicenter study.

Front Immunol · 2025 · PMC12827712 · PMID 41583427

Europe PMC DOI

hedged sentence

0.0100

closest p · 0.2× alpha

0.0100

boldest claim

The sentences

showed a trendp = 0.01actually significant

Moreover, when examining the treatment modalities during rechallenge, combination therapy showed a trend toward longer PFS (7.4 vs . 2.9 months, HR = 0.33, 95%CI = 0.05–0.54, p = 0.01) and OS (11.0 vs . 5.0 months, HR = 0.34, 95%CI = 0.06–0.80, p = 0.03) compared with cadonilimab monotherapy ( Figures 3E, F ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.